anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a promoter for the proliferation of lactic acid bacteria as an active ingredient, comprising a water-insoluble fiber, capable of selectively proliferating the lactic acid bacteria of genus Bifidoibacterium and having improving effects on both intestinal floras and dejection. SOLUTION: This promoter for the proliferation of lactic acid bacteria comprises a water-insoluble fiber, especially the one contained in a cacao bean and a cacao husk which is an exodermis thereof as an active ingredient. The water-insoluble fiber is obtained by extracting the cacao bean or cacao husk which is the exodermis with water or further an organic solvent, preferably ethanol and removing water-soluble substances therefrom. Since the flavor of the cacao remains in the resultant water-insoluble fiber simply by extraction thereof with water, the extraction with water is preferably used together with the extraction with the organic solvent. The tasteless and odorless objective substance can be added to various foods. Since the cacao husk has hitherto been discarded, the promoter can be produced at a low cost.
Chronic inflammation is a recognized risk factor for various cancers, including prostate cancer (PCa). We aim to explore the potential protective effects of aged black garlic extract (ABGE) against inflammation-induced prostate damage and its impact on prostate cancer cell lines. We used an ex vivo model of inflammation induced by Escherichia coli lipopolysaccharide (LPS) on C57BL/6 male mouse prostate specimens to investigate the anti-inflammatory properties of ABGE. The gene expression levels of pro-inflammatory biomarkers (COX-2, NF-κB, and TNF-α, IL-6) were measured. Additionally, we evaluated ABGE's therapeutic effects on the prostate cancer cell lines through in vitro functional assays, including colony formation, tumorsphere formation, migration assays, and phosphorylation arrays to assess the signaling pathways (MAPK, AKT, JAK/STAT, and TGF-β). ABGE demonstrated significant anti-inflammatory and antioxidant effects in preclinical models, partly attributed to its polyphenolic content, notably catechin and gallic acid. In the ex vivo model, ABGE reduced the gene expression levels of COX-2, NF-κB, TNF-α, and IL-6. The in vitro studies showed that ABGE inhibited cell proliferation, colony and tumorsphere formation, and cell migration in the prostate cancer cells, suggesting its potential as a therapeutic agent. ABGE exhibits promising anti-inflammatory and anti-cancer properties, supporting further investigation into ABGE as a potential agent for managing inflammation and prostate cancer.
A tubing set for a blood processing system includes a first connector, a first tube, and a second tube. The first connector is configured to connect to a separation device within the blood processing system, and has a first inlet configured to be fluidly connected to an outlet of the separation device. The first connector also has an outlet and a second inlet. The first tube fluidly connects to the outlet and fluidly connects the separation device and a blood component storage container. The second tube is fluidly connected to the second inlet and fluidly connects the separation device and a saline storage container. The second tube may include a second connector that connects to the saline storage container.
PURPOSE: A body care product containing a body care composition containing Momordica charantia fermentation extract and a method for manufacturing the same are provided to ensure low irritation and to improve skin immunity. CONSTITUTION: A body care composition contains Momordica charantia fermentation extract prepared by fermenting Momordica charantia using Zygosaccharomyces bailii TS-201201(KACC93148P). A body care product contains the body care composition. The body care product is a liquid soap, solid soap, granules, powder, aroma bag, or cream. A method for preparing a Momordica charantia fermentation comprises a step of fermenting Momordica charantia or Momordica charantia concentrate using Zygosaccharomyces bailii. The Momordica charantia concentrate is prepared by concentrating hot water extract of Momordica charantia. [Reference numerals] (AA) Momordica charantia 1; (BB) Momordica charantia 2
Objectives: 1) To demonstrate that circulating CD45+ CD34+ CD11b+ cells can express Procollagen 1 and thereby show that these markers can be used to identify circulating fibrocytes. 2) To measure the levels of circulating CD45+, CD34+, CD11b+ cells in patients with RA, Fibrotic ILDs, severe asthma and in healthy controls (HC). 3) To compare the levels with number of peripheral blood mononuclear cells (PBMC) that differentiate to mature fibrocytes in vitro.

Method: The CD45+, CD34+, CD11b+ cells from 4 patients were isolated by cell sorting, and stained for Procollagen. 30 patients (10 of each RA, fibrotic ILDs: IPF or non-specific interstitial pneumonitis (NSIP), severe asthma) and 10 HC were included. Current medication, disease activity, lung function and radiographic data were collected. In 100 µL of lysed blood cells were enumerated by flowcytometry. Further, PBMC were isolated and cultured for 5 days. Coverslips from two wells were stained and mature fibrocytes counted and reported as fibrocytes per 106 PBMC originally added to the well.
The present invention discloses a composition of Tibet medicine containing salt and a preparation method thereof. The composition has a health care function. The composition of Tibet medicine contains salt, juniper, myricaria germanica, rhododendron, large seed artemisia, etc. A medicinal bath salt product prepared by the method of the present invention has the advantages of stable technology and high and controlled quality, and is favorable for ensuring a therapeutic effect. The bath salt of the present invention has the efficacy of expelling rheumatism, tranquilizing spirit, promoting sleep, beautifying faces, reducing weight and increasing immunization. The bath salt of the present invention can promote the blood circulation of a body, increase heat energy, and resist chill invasion, and the bath salt of the present invention has the efficacy of coolness and heat clearing in summer.
BACKGROUND: Aspiration pneumonitis (AP) secondary to cerebrospinal fluid (CSF) leak is underestimated and rarely discussed. This study aimed to evaluate the association between AP and CSF leaks.
METHODS: Clinical and surgical characteristics of CSF leak patients with and without AP between January 2010 and December 2022 were included and compared.
RESULTS: This study included 159 patients, 16 with CSF otorrhea and 143 with CSF rhinorrhea. Among them, 40 (25.2%) had AP. Bilateral pneumonitis was identified in 32 cases, of which 11 showed severe pneumonitis in the right upper lung lobe. Twenty-one (52.5%) asymptomatic and 19 (47.5%) symptomatic cases were documented. The major clinical manifestations included cough (n = 19, 47.5%) and expectoration (n = 9, 22.5%). The prevalence of pneumonitis was significantly higher in the spontaneous group than in the traumatic group. High-flow CSF leak was associated with AP (42.5% vs. 16.8%, p = 0.001). No significant differences were identified in defect locations between patients with and without AP. Patients with pneumonitis had a higher prevalence of meningitis (32.5% vs. 12.6%, p = 0.003). Multiple logistic regression results revealed that meningitis, spontaneous and high-flow CSF leaks are independent factors for AP occurrence. Both the CSF leak and pulmonary complications resolved following successful surgical repair.
CONCLUSIONS: AP secondary to CSF leaks is frequently underdiagnosed, with a higher incidence identified in spontaneous cases. The occurrence of AP was associated with high-flow CSF leak.
KEY POINTS: A pneumonitis rate of 25.2% in cerebrospinal fluid (CSF) leak patients was reported for the first time. A higher prevalence of aspiration pneumonitis was identified in spontaneous CSF leak. Meningitis, spontaneous and high-flow CSF leaks are independent factors for aspiration pneumonitis occurrence.
Insomnia is common in adults with chronic heart failure (HF), a condition associated with functional performance deficits, symptom burden, and high levels of morbidity and mortality. To date there has been little study of strategies to improve sleep in this large population. Cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for insomnia comorbid with several medical and psychiatric disorders, but has not been tested in HF. The purpose of this exploratory developmental research is to test the feasibility, acceptability, and size of the effects of CBT-I on subjective and objective characteristics of sleep and insomnia symptoms and functional performance in patients with stable HF. Forty patients with stable HF will be randomized to 7 weeks of CBT-I or 7-weeks of HF self-management education with sleep hygiene (attention control). Subjective (diaries, questionnaires) and objective (wrist actigraphy) characteristics of sleep; symptoms, and self-reported functional performance will be measured pre- and post-intervention. The investigators will also obtain day and night measures of urinary free cortisol, free epinephrine/norepinephrine, and melatonin sulfate. They will: 1) refine the protocol, procedures, patient materials, and training manual for the CBT-I intervention and a group HF self-management class (attention-control); 2) evaluate the feasibility and acceptability of the CBT-I intervention and the attention-control conditions; 3) evaluate the size of the effects of group CBT-I, compared with attention-control, on objective (actigraph) and subjective (questionnaire and sleep diary) sleep characteristics, self-report of insomnia symptoms, and beliefs and attitudes about sleep; and 4) evaluate the size of the effects of CBT-I, compared with attention-control, on daytime symptoms (fatigue, depression, anxiety, excessive daytime sleepiness) and functional performance. The primary outcome will be self-reported sleep continuity (sleep efficiency). Investigators will also explore the effects of changes in characteristics of sleep and insomnia symptoms on symptoms and daytime function; the effects of CBT-I, compared with attention control, on nocturnal symptoms, and the effects of CBT-I, compared with attention control, on biological indicators of nocturnal and daytime Hypothalamic Adrenal Pituitary axis (urinary free cortisol), sympathetic nervous system (urinary epinephrine/norepinephrine, and pineal (urinary melatonin) function. The results will be used to support design decisions for a future larger scale efficacy study and may ultimately lead to translation of CBT-I into the care of patients with HF.
At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with PAXIL. Conversely, at least 14 days should be allowed after stopping PAXIL before starting an MAOI antidepressant (see CONTRAINDICATIONS).

Use of PAXIL With Reversible MAOIs Such as Linezolid or Methylene Blue:Do not start PAXIL in a patient who is being treated with linezolid or methylene blue because there is increased risk of serotonin syndrome or NMS-like reactions. In a patient who requires more urgent treatment of a psychiatric condition, non-pharmacological interventions, including hospitalization, should be considered (see CONTRAINDICATIONS). In some cases, a patient receiving therapy with PAXIL may require urgent treatment with linezolid or methylene blue. If acceptable alternatives to linezolid or methylene blue treatment are not available and the potential benefits of linezolid or methylene blue treatment are judged to outweigh the risks of serotonin syndrome or NMS-like reactions in a particular patient, PAXIL should be stopped promptly, and linezolid or methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome or NMS-like reactions for 2 weeks or until 24 hours after the last dose of linezolid or methylene blue, whichever comes first. Therapy with PAXIL may be resumed 24 hours after the last dose of linezolid or methylene blue (see WARNINGS).
Disclosed herein are methods for improving gastrointestinal barrier function, alleviating a gastrointestinal barrier dysfunction-associated disorder, and inhibiting growth of enteric pathogenic bacteria using a composition containing  Lactobacillus rhamnosus  MP108,  Bifidobacterium longum  subsp.  infantis  BLI-02, and  Bifidobacterium animalis  subsp.  lactis  BB-115, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) respectively under accession numbers CGMCC 21225, CGMCC 15212, and CGMCC 21840. A number ratio of  Lactobacillus rhamnosus  MP108,  Bifidobacterium longum  subsp.  infantis  BLI-02, and  Bifidobacterium animalis  subsp.  lactis  BB-115 ranges from 1:0.2:0.67 to 1:9:9.
FIELD: medicine, pharmacognosy. SUBSTANCE: the method deals with standardization and quality control of multi-component plant species. Microscopic detection of components' content is conducted by using a stage for obtaining a homogeneous sample of species' powder mixture due to a 5-10-fold turning over of the analyzed sample in a reservoir at the ratio of sample weight/reservoir volume being 1:5-15, and participation index is calculated by relation of diagnostically valuable particles of a component to their combination in the species. The method enables to increase the accuracy of quality control and simplicity at standardization of plant species. EFFECT: higher reliability of detection. 1 cl, 4 tbl
The present invention relates to a composition for preventing or treating porcine epidemic diarrhea virus infection containing an extract of Ulmus davidiana var. japonica supercritical extract residue, and a Chamaecyparis obtusa oil water complex as active components. The content of active component of the extract of Ulmus davidiana var. japonica supercritical extract residue is higher than the content of active component of an Ulmus davidiana var. japonica extract, and the composition containing the extract of Ulmus davidiana var. japonica supercritical extract residue and the Chamaecyparis obtusa oil water complex has excellent prevention or treatment effect of porcine epidemic diarrhea virus infection.
The invention discloses a compound dandelion decoction. According to the product, based on a secret prescription handed down from ancestors, 50 kg of fresh dandelion herbs is pulverized into paste and is squeezed; and 36 kg of juice is taken and is mixed with 21 pure traditional Chinese medicines such as honeysuckle, radix sophorae flavescentis and mint to prepare 12 kg of light yellow liquid decoction which tastes slightly bitter, sweet and salty and is an active remedy special for treating skin diseases for both young and old. The compound dandelion decoction has the functions of clearing heat and detoxifying, activating blood circulation to dissipate blood stasis, diminishing inflammation and relieving pain, killing insects and relieving itching, suppressing fungi, removing rotten skin and engendering flesh, resisting against infection and moistening skin and the like; and the red and swollen skin gradually becomes dark, the wound is converged, the pain and itching are gradually relieved, and a patient gradually feels comfortable after the compound dandelion decoction is coated for almost one minute. The compound dandelion decoction has an obvious curative effect for acute exudative skin diseases, can heal in 2-5 days and has the curative effect of basically 100 percent; and the compound dandelion decoction can be used for healing the intractable skin diseases in a short time, and the curative effect is over 98 percent. The compound dandelion decoction can be dropwise put in eyes and melted in mouth, and has an obvious curative effect on inflammation and ulcer of the mouth and the eyes. The compound dandelion decoction has no preservative capacity and a proper amount of edible preservative is suitable for being added. The fresh residue can be used for feeding pigs; and the decocted residues can be used as an organic fertilizer for farm crops.
In this experimental condition, Salvation Army personnel will implement an incentive strategy designed to encourage Salvation Army consumers to accept immediate referral to the WTQL. The incentive strategy will be adapted by Salvation Army personnel to fit in the local context, and staff will receive training and ongoing support in implementation of the incentive strategy. The modest incentives will be added in a staggered manner across the 2 Salvation Army sites participating in this pilot trial, after at least 3 months of implementing WTQL referral without consumer incentives for immediate calls.
The aging of the global population poses significant scientific challenges. Moreover, the biological process of aging is the most significant risk factor for most chronic illnesses; therefore, understanding the molecular and cellular mechanisms underlying these aging-related challenges is crucial for extending the healthy lifespan of older individuals. Preventing brain aging remains a priority public health goal, and integrative and comprehensive aging analyses have revealed that immunosenescence is a potential cause of age-related brain damage and disease (e.g., stroke). Importantly, the neuroinflammatory and immune systems present two-way contact and thus can affect each other. Emerging evidence supports the numerous effects of immunosenescence- and inflammation-mediated immunity in neurologically injured brains. In this study, we briefly outline how aging alters the pathophysiology and transcriptional amplitude in patients who experienced stroke and then discuss how the immune system and its cellular components and molecular mechanisms are affected by age after stroke. Finally, we highlight emerging interventions with the potential to slow down or reduce aging and prevent stroke onset.
Patients who had a breast cancer diagnosis (including those with ductal carcinoma in situ (DCIS)), who were age ≥18 years at the time of diagnosis and identify as a gender and/or sex that is different from their sex assigned at birth (e.g., transgender, nonbinary, genderqueer, etc.) between 1/1/1990 - 7/1/2023.
The invention provides a microneedle wound plaster for preventing scars, which consists of a needle point, a separation layer, a basal layer and an antibacterial hydrogel dressing. The needle tip of the microneedle wound plaster is loaded with effective components capable of promoting vascularization of open wounds and inhibiting formation of fibrous tissues, and can be implanted into the skin. Through the rapid reaction of the separation layer loaded with the anesthetic component and the degradable magnesium particles and body fluid, the separation of the needle tip and the microneedle substrate layer, the full contact of the wound and oxygen and the rapid anesthesia of the wound are realized, and the effects of inhibiting bacteria, rapidly relieving pain and inhibiting scar formation are achieved. The needle tip and the separation layer are both used as drug-loaded layers and respectively loaded with components with two effects of inhibiting scars and quickly anaesthetizing. The moist bacteriostatic hydrogel dressing can accelerate the dissolution of the microneedle substrate layer while inhibiting bacteria, and obviously improves the implantation speed of the microneedle. The needle point and the bacteriostatic hydrogel dressing are both prepared from high polymer material chitosan, and the separation layer is prepared from hydrophilic high polymer material and magnesium particles. The invention also provides a preparation method of the microneedle wound plaster for preventing scars, which is simple in process and low in cost.
Research suggests that at least 1 in 10 Veterans will meet criteria for posttraumatic stress disorder (PTSD) related to their military experience. Treatment is widely available to Veterans with PTSD, and national dissemination initiatives have increased Veterans' access to best practice interventions. However, treatment seeking remains strikingly low among Veterans with PTSD. In fact, most Veterans with PTSD do not seek mental health services due to perceived stigma and other associated barriers. The National Center for PTSD recently developed and launched AboutFace, a peer education resource for Veterans. The investigators of this study believe that AboutFace has tremendous potential to reduce stigma and improve attitudes toward seeking mental health services among Veterans. However, it has not yet been evaluated. Investigators have partnered with the National Center for PTSD to launch this mixed methods pilot evaluation of AboutFace. There will be two phases to this study. During Phase I- Usability, 20 Veterans will be recruited to participate in individual interviews during which they will be asked to describe the ease of use of the AboutFace website for the researchers. During Phase II- Feasibility, 60 Veterans will be randomized to one of two conditions- About Face or Usual Care. All participants will complete several brief assessments measuring PTSD symptoms and attitudes toward seeking mental health services. Participants will then be randomized to either receive a link to the About Face website or to receive a link to a general online brochure about PTSD. After two weeks, participants will complete the assessment measures once again to determine any changes in attitudes toward seeking mental health services and potential changes in PTSD symptoms.
Glucocorticoids (GCs) are commonly used in the treatment of chronic inflammatory conditions. However, the administration of high doses and long-term use of GCs can induce muscle atrophy (MA) in patients, leading to a decline in quality of life and increased mortality. MA leads to protein degradation in skeletal muscle, resulting in a reduction of muscle mass. This process is triggered by GCs like dexamethasone (DEX), which induce the expression of E3 ubiquitin ligases, namely Atrogin-1 and muscle RING-finger protein-1 (MuRF1). In this study, we examined the anti-MA potential of Luffa cylindrica Roemer (LCR) on DEX-treated primary skeletal myotubes. Primary skeletal myotubes stimulated with LCR alone resulted in a significant upregulation of myotube development, characterized by an increase in both the number and diameter of myotubes. Contrastingly, combined treatment with LCR and DEX reduced the expression of Atrogin-1, while treatment with DEX alone induced the expression of MuRF1. Furthermore, LCR treatment successfully restored the number and diameter of myotubes that had been diminished by DEX treatment. These findings suggest that LCR holds potential for treating MA, as an accelerating effect on muscle development and anti-MA effects on primary skeletal muscle cells were observed.
PURPOSE:An antiallergic suppressing specifically production of IgE caused by allergic disease, having high safety, containing an epoxy-succinic acid derivative as an active ingredient. CONSTITUTION:An antiallergic containing a compound shown by the formula (R<1> is H, or ethyl; R<2> is butyl replaced with guanidyl, amino, methyl, etc.) as an active ingredient. Allergic diseases are caused by production of IgE, the compound shown by the formula suppresses specifically only production of IgE, and not suppresses immunoglobulin (IgG, or IgM) in charge of normal immunological reactions. A does as an antiallergic is 10-500mg per time calculated as the compound shown by the formula I , and it is administered 2-3 times daily. It was found that acute toxicity of the compound shown by the formula I has extremely high safety of LD50>2,000mg/kg in mouse.